Guiyang Xintian Pharmaceutical Co.,Ltd. (002873.SZ)
CNY 8.67
(0.58%)
CNY 8.67
(0.58%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 602 Million CNY | 23.83% |
| 2022 | 486.17 Million CNY | 13.12% |
| 2021 | 429.78 Million CNY | -23.86% |
| 2020 | 564.43 Million CNY | 121.81% |
| 2019 | 254.47 Million CNY | 19.6% |
| 2018 | 212.77 Million CNY | 51.43% |
| 2017 | 140.5 Million CNY | -26.9% |
| 2016 | 192.21 Million CNY | -3.7% |
| 2015 | 199.6 Million CNY | -7.76% |
| 2014 | 216.4 Million CNY | 45.63% |
| 2013 | 148.6 Million CNY | 37.59% |
| 2012 | 108 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 710.83 Million CNY | 3.1% |
| 2024 Q2 | 697.07 Million CNY | -2.3% |
| 2024 Q1 | 713.48 Million CNY | 18.52% |
| 2023 Q3 | 672.24 Million CNY | 7.89% |
| 2023 Q4 | 602 Million CNY | -10.45% |
| 2023 FY | 602 Million CNY | 23.83% |
| 2023 Q1 | 547.91 Million CNY | 12.7% |
| 2023 Q2 | 623.07 Million CNY | 13.72% |
| 2022 Q3 | 423.36 Million CNY | -5.4% |
| 2022 Q2 | 447.52 Million CNY | -1.05% |
| 2022 Q1 | 452.25 Million CNY | 5.23% |
| 2022 FY | 486.17 Million CNY | 13.12% |
| 2022 Q4 | 486.17 Million CNY | 14.84% |
| 2021 FY | 429.78 Million CNY | -23.86% |
| 2021 Q4 | 429.78 Million CNY | -6.7% |
| 2021 Q2 | 493.54 Million CNY | -8.8% |
| 2021 Q1 | 541.16 Million CNY | -4.12% |
| 2021 Q3 | 460.66 Million CNY | -6.66% |
| 2020 Q4 | 564.43 Million CNY | 11.91% |
| 2020 FY | 564.43 Million CNY | 121.81% |
| 2020 Q1 | 419.21 Million CNY | 64.74% |
| 2020 Q2 | 503.37 Million CNY | 20.08% |
| 2020 Q3 | 504.37 Million CNY | 0.2% |
| 2019 Q2 | 223 Million CNY | 6.67% |
| 2019 FY | 254.47 Million CNY | 19.6% |
| 2019 Q4 | 254.47 Million CNY | -10.55% |
| 2019 Q3 | 284.5 Million CNY | 27.58% |
| 2019 Q1 | 209.05 Million CNY | 0.0% |
| 2018 Q1 | 169 Million CNY | 20.28% |
| 2018 Q2 | 195.5 Million CNY | 15.68% |
| 2018 FY | 212.77 Million CNY | 51.43% |
| 2018 Q3 | 209.05 Million CNY | 6.93% |
| 2018 Q4 | 209.05 Million CNY | 0.0% |
| 2017 Q4 | 140.5 Million CNY | -25.66% |
| 2017 FY | 140.5 Million CNY | -26.9% |
| 2017 Q1 | 167.71 Million CNY | -12.75% |
| 2017 Q2 | 196 Million CNY | 16.86% |
| 2017 Q3 | 189 Million CNY | -3.57% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 192.21 Million CNY | 0.0% |
| 2016 FY | 192.21 Million CNY | -3.7% |
| 2016 Q2 | 186.81 Million CNY | 0.0% |
| 2015 Q3 | 199.6 Million CNY | -0.4% |
| 2015 Q4 | 199.6 Million CNY | 0.0% |
| 2015 Q2 | 200.4 Million CNY | 0.0% |
| 2015 Q1 | 200.4 Million CNY | -7.39% |
| 2015 FY | 199.6 Million CNY | -7.76% |
| 2014 FY | 216.4 Million CNY | 45.63% |
| 2014 Q4 | 216.4 Million CNY | 0.0% |
| 2014 Q3 | 216.4 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2013 FY | 148.6 Million CNY | 37.59% |
| 2012 FY | 108 Million CNY | 0.0% |